Winners and losers. Is the U.S. really an HCE outlier? Superbugs. No IO in UK? Basic income’s version of the RAND HIE. What is CAR-T?
Demoted in DC. Is big government not big enough? World’s most internationally revered money-laundering scam? Workers’ Comp golden rule. Bird flu in China.
New hope for cancer treatment? Strategic drug filling around Medicare eligibility date. Unlearning descriptive statistics. Fighting antibiotic-resistant bacteria. Cost disease.
Cardiologists, oncologists decry travel ban Treating chronic illness. Pancreatic cancer breakthrough? Statins can treat cancer? Cancer screening and cost sharing. The problem of polypharmacy.
In honor of inauguration day, some Trump-relevant links: “Art of the Deal” in health care Trump and speculative markets. On “repeal and replace” (with Wile E. Coyote graphic) Will Trump cut public health funding? Trump’s HHS appointee.
Why your city has no money. The “words matter” HWR The AI poker player? Should anti-vaccine MDs lose their license? The dental-medical divide.
Wine and breast cancer. The promise of molecular imaging. The world’s most expensive drug? Who will be the binding constraint for drug access? 7 stages of robot replacement.
A “shadowy crony group”? The real 2016 celebrity deaths. “The GOP isn’t going to repeal ACA.” Economists versus the Economy. Art of the Deal coming to Rx?
Unified theory of scarcity. Will price transparency cut costs? Potential. Surprise bills. Should academics partner with industry? Giannis!
Does risk aversion change after a health shock. DCE vs. BWS. Does insurance cause high pharmaceutical prices? The latest developments in P4P. Drug prices rise, but ROI falls?